Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study

Christian Buske, MD, Alessandra Tedeschi, MD, Judith Trotman, FRACP, Ramon García-Sanz, MD PhD, David MacDonald, MD, Véronique Leblond, MD PhD, Beatrice Mahe, MD, Charles Herbaux, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, M. Lia Palomba, MD, Jeffrey V Matous, MD, Chaim Shustik, MD, Eftathios Kastritis, MD, Steven P Treon, MD PhD FRCP, Chih-Jian Lih, PhD, Jianling Li, MS, Zeena Salman, BS, Thorsten Graef, MD PhD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 149.

https://doi.org/10.1182/blood-2018-99-111178

Published: 2018

Journal Articles

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, Saulius Girnius, MD, Saurabh Chhabra, MD, Robert Frank Cornell, MD, Cristina J. Gasparetto, MD, Chatchada Karanes, MD, Matthew A. Lunning, DO, Jeffrey V. Matous, MD, Ruben Niesvizky, MD, Chaim Shustik, MD, Robert K. Stuart, MD, Jason Lih, PhD, Yihua Lee, PhD, Zeena Salman, Thorsten Graef, MD PhD, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 3111.

https://doi.org/10.1182/blood.V130.Suppl_1.3111.3111

Published: 2017

Journal Articles

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Blood (2015) 126 (23): 2745.

https://doi.org/10.1182/blood.V126.23.2745.2745

Published: 2015

Journal Articles

Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia

Christian Buske, Shalal Sadullah, FRCP, FRCPath, Efsthatios Kastritis, MD, Giulia Benevolo, MD, Ramon Garcia-Sanz, MD, Lukasz Bolkun, MD PhD, Xavier Leleu, MD PhD, Wolfgang Willenbacher, MD, Roman Hajek, MD, Ellen van der Spek, MD PhD, Mei Cheng, PhD, Thorsten Graef, MD PhD, Meletios A. Dimopoulos, MD

Blood (2015) 126 (23): 2096.

https://doi.org/10.1182/blood.V126.23.2096.2096

Published: 2015

Journal Articles

Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

Vincent Ribrag, MD, Won Seog Kim, MD PhD, Reda Bouabdallah, MD, Soon Thye Lim, MBBS, MRCP, Bertrand Coiffier, Zakia Felloussi, Ioana Kloos, Ying Luan, PhD, Thorsten Graef, MD PhD, Franck Morschhauser, MD

Blood (2015) 126 (23): 256.

https://doi.org/10.1182/blood.V126.23.256.256

Published: 2015

Journal Articles

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ajai Chari, MD, Saurabh Chhabra, MD, Saad Usmani, MD, Sarah Larson, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Cristina Gasparetto, MD, Beata Holkova, MD, Matthew Lunning, DO, Jason Valent, MD, Larry D. Anderson, Jr., MD PhD, Chatchada Karanes, MD, Long Kwei, PhD, Lipo Chang, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Kevin McDonagh, MD

Blood (2015) 126 (23): 377.

https://doi.org/10.1182/blood.V126.23.377.377

Published: 2015

Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson

Blood (2014) 124 (21): 31.

https://doi.org/10.1182/blood.V124.21.31.31

Published: 2014

Journal Articles

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

Jennifer R Brown, MD, PhD, Jaqueline C. Barrientos, MD, Paul M. Barr, MD, Ian Flinn, MD, PhD, Jan A. Burger, MD, PhD, Zeena Salman, Fong Clow, ScD, Danelle F. James, MD, Thorsten Graef, MD, PhD, Jonathan W. Friedberg, MD, Kanti R. Rai, M.D., Susan O'Brien, MD

Blood (2013) 122 (21): 525.

https://doi.org/10.1182/blood.V122.21.525.525

Published: 2013

Journal Articles

Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial

Meletios Athanasios Dimopoulos, MD, Sundar Jagannath, MD, Sung-Soo Yoon, MD, PhD, David S. Siegel, MD, PhD, Sagar Lonial, MD, Roman Hajek, MD, PhD, Thierry Facon, MD, Laura Rosiñol, MD, Hilary Anne Blacklock, MD, Hartmut Goldschmidt, MD, Vania Hungria, MD, Andrew Spencer, MD, Antonio Palumbo, MD, Donna E. Reece, MD, FRCPC, Thorsten Graef, MD, PhD, Jennifer Houp, Linda Sun, PhD, Joseph E. Eid, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 811.

https://doi.org/10.1182/blood.V118.21.811.811

Published: 2011

Journal Articles

Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,

Joshua R. Richter, MD, Elizabeth Bilotti, MSN, RN, Laura McBride, Linda Schmidt, Zhijie Gao, MD, Madiha Tufail, MD, Palka Anand, Ann McNeill, Urszula Bednarz, Thorsten Graef, MD, PhD, David H. Vesole, MD, PhD, David S. Siegel, MD, PhD

Blood (2011) 118 (21): 3986.

https://doi.org/10.1182/blood.V118.21.3986.3986

Published: 2011

Journal Articles

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

David S. Siegel, MD, PhD, Meletios Athanasios Dimopoulos, MD, Sung-Soo Yoon, MD, PhD, Jacob P. Laubach, MD, Jonathan L. Kaufman, MD, Hartmut Goldschmidt, MD, Donna E. Reece, MD, FRCPC, Xavier Leleu, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Fritz C. Offner, MD, PhD, Michele Cavo, MD, Arnon Nagler, MD, Sundar Jagannath, MD, Thorsten Graef, MD, PhD, Jennifer Houp, Linda Sun, PhD, Jason Howe, Sandra M. Wear, RN, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 480.

https://doi.org/10.1182/blood.V118.21.480.480

Published: 2011

Journal Articles

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

Paul Richardson, MD, Donna Weber, MD, Constantine S. Mitsiades, MD, PhD, Meletios A. Dimopoulos, MD, Jean-Luc Harousseau, MD, Jennifer Houp, Thorsten Graef, MD, PhD, Christine K Gause, Catriona Byrne, Kenneth C. Anderson, MD, David Siegel, MD, PhD

Blood (2010) 116 (21): 1951.

https://doi.org/10.1182/blood.V116.21.1951.1951

Published: 2010

Journal Articles

Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program

David S Siegel, MD, PhD, Sundar Jagannath, MD, Roman Hajek, MD, PhD, Meletios A. Dimopoulos, MD, Sung-Soo Yoon, MD, PhD, Sagar Lonial, MD, Jacob P. Laubach, MD, MPP, Thorsten Graef, MD, PhD, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Kenneth C. Anderson, MD

Blood (2010) 116 (21): 1952.

https://doi.org/10.1182/blood.V116.21.1952.1952

Published: 2010

Journal Articles

Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma

David Samuel diCapua Siegel, MD, PhD, Laura McBride, Elizabeth Bilotti, MSN, RN, Linda Schmidt, Zhijie Gao, MD, Madiha Tufail, MD, Nikoletta Lendvai, MD, PhD, Ann McNeill, Kristen Donadio, Karly Olivo, Urzula Bednarz, Thorsten Graef, MD, PhD, David H. Vesole, MD, PhD

Blood (2010) 116 (21): 3065.

https://doi.org/10.1182/blood.V116.21.3065.3065

Published: 2010

Journal Articles

Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

David Siegel, Sundar Jagannath, MD, Sagar Lonial, MD, Meletios A. Dimopoulos, Thorsten Graef, MD, PhD, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Syed Rizvi, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3890.

https://doi.org/10.1182/blood.V114.22.3890.3890

Published: 2009

Journal Articles

Fludarabine, Amsacrine, High-Dose Cytarabine and Total Body Irridation Followed by Allogeneic Stem Cell Transplantation for the Treatment of High Risk or Relapsed Acute Lymphoblastic Leukemia.

Fabian Zohren, MD, Thorsten Graef, MD, Ingmar Bruns, MD, Akos Czibere, MD, Fenk Roland, MD, Haas Rainer, MD, Kobbe Guido

Blood (2007) 110 (11): 5086.

https://doi.org/10.1182/blood.V110.11.5086.5086

Published: 2007

Journal Articles

Sequential Induction Chemotherapy, and Early Intensified Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Myeloid Leukemia.

Thorsten Graef, MD, Nikola Schmittner, Frank Neumann, MD, Roland Fenk, MD, Fabian Zohren, MD, Akos Czibere, MD, Norbert Gattermann, MD, Rainer Haas, MD, Guido Kobbe, MD

Blood (2006) 108 (11): 5367.

https://doi.org/10.1182/blood.V108.11.5367.5367

Published: 2006

Journal Articles

Combined Use of Palifermin and Pegfilgrastim Significantly Reduces Toxicity of High-Dose Therapy and Autologous Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

Guido Kobbe, MD, Nadine Hieronimus, Thorsten Graef, MD, Ingmar Bruns, MD, Arcos Cibere, MD, Fabian Zohren, MD, Ulrich Steidl, MD, Ulrich Germing, MD, Rainer Haas, MD, Roland Fenk, MD

Blood (2006) 108 (11): 5260.

https://doi.org/10.1182/blood.V108.11.5260.5260

Published: 2006

Journal Articles

5-Azacitidine in Combination with Donor Lymphocyte Infusions for the Treatment of Patients with MDS or AML Relapsing after Allogeneic Stem Cell Transplantation.

Akos Czibere, MD, Thorsten Graef, MD, Jens Lind, Norbert Gattermann, MD, Fabian Zohren, MD, Roland Fenk, MD, Rainer Haas, MD, Guido Kobbe, MD

Blood (2006) 108 (11): 5341.

https://doi.org/10.1182/blood.V108.11.5341.5341

Published: 2006

Journal Articles

Escalation Treatment Algorithm with Bortezomib, Dexamethasone and Bendamustine for Patients with Relapsed or Refractory Multiple Myeloma: A Singel Centre Experience.

Roland Fenk, MD, Mark Michael, Fabian Zohren, Thorsten Graef, MD, Arkosch Czibere, MD, Sebastian Balleisen, MD, Frank Neumann, MD, Ulrich-Peter Rohr, MD, Ulrich Steidl, MD, Rainer Haas, MD, Guido Kobbe, MD

Blood (2006) 108 (11): 3540.

https://doi.org/10.1182/blood.V108.11.3540.3540

Published: 2006

NARROW

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia

Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial

Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program

Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma

Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

Fludarabine, Amsacrine, High-Dose Cytarabine and Total Body Irridation Followed by Allogeneic Stem Cell Transplantation for the Treatment of High Risk or Relapsed Acute Lymphoblastic Leukemia.

Sequential Induction Chemotherapy, and Early Intensified Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Myeloid Leukemia.

Combined Use of Palifermin and Pegfilgrastim Significantly Reduces Toxicity of High-Dose Therapy and Autologous Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

5-Azacitidine in Combination with Donor Lymphocyte Infusions for the Treatment of Patients with MDS or AML Relapsing after Allogeneic Stem Cell Transplantation.

Escalation Treatment Algorithm with Bortezomib, Dexamethasone and Bendamustine for Patients with Relapsed or Refractory Multiple Myeloma: A Singel Centre Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only